VN February 2021
Vetnews | February 2021 39 The aims of this study by Katrin Smith and others were to calculate buffalo-specific thresholds for different TST criteria (SITT, SICTT, and SICTT72h that calculates the differential change at 72 h only) and compare performance using these cut-off values. Effective screening methods are critical for preventing the spread of bovine tuberculosis (bTB) among livestock and wildlife species. The tuberculin skin test (TST) remains the primary test for bTB globally, although performance is suboptimal. African buffaloes ( Syncerus caffer ) are a maintenance host of Mycobacterium bovis in South Africa, tested using the single intradermal tuberculin test (SITT) or comparative test (SICTT). The interpretation of these tests has been based on cattle thresholds due to the lack of species-specific cut-off values for African buffaloes. The results confirm that 3 mm best discriminates M. bovis -infected from unexposed control buffaloes with sensitivities of 69 % (95 % CI 60–78; SITT and SICTT) and 76 % (95 % CI 65–83; SICTT72h), and specificities of 86 % (95 % CI 80–90; SITT), 96 % (95 % CI 92–98; SICTT72h) and 97 % (95 % CI 93–99; SICTT), respectively. A comparison between TST criteria using buffalo-specific thresholds demonstrates that the comparative TST performs better than the SITT, although sensitivity remains suboptimal. Therefore, further research and the addition of ancillary tests, such as cytokine release assays, are necessary to improve M. bovis detection in African buffaloes. v Optimisation of the tuberculin skin test for detection of Mycobacterium bovis in African buffaloes (Syncerus caffer) Recent Clinically Relevant Research from Around theWorld This survey of equine veterinarians by Amie Wilson and colleagues aimed to describe current vaccination practices advised by vets treating horses in the UK and compare practices with manufacturer datasheets and current guidelines. A survey completed by 304 UK equine vets working with a variety of horse populations identified that the recommendations given to owners by the majority of respondents (92%) were not consistent with datasheet guidelines. Vaccination guidelines from the British Horseracing Authority and the Fédération Equestre Internationale were most commonly used. Variation was also identified in vaccine protocols for competition and non‐competition horses, with 57% of respondents reporting variation in advised ‘booster’ frequency. This most commonly consisted of advising 6‐monthly vaccination in competition horses and annual vaccination in non‐competition horses. Adverse events following vaccination in the previous year were encountered by 66% of respondents, representing 2760 adverse events in total. Only 526 (19%) of reactions were reported to the Veterinary Medicines Directorate. The most common reactions were transient, including stiffness (n = 931), localised swelling (n = 835), lethargy (n = 559) and pyrexia (n = 355). A large proportion (86%) of respondents reported vaccine hesitancy from horse owners, most commonly due to perception of over‐vaccination, cost and concerns regarding adverse events. A discrepancy exists between datasheet guidelines and those issued by industry governing bodies. Non‐compliance with the datasheet guidelines is common, risking suboptimal immunity to equine influenza. v EQUINE Equine influenza vaccination in the UK (Sources: Equine Veterinary Education) This longitudinal randomised field trial by Martin Nielsen and colleagues in the USA and NewZealand evaluated egg count levels, bodyweight, and equine health under defined parasite control protocols in foals andmares at four stud farms inNewZealand. Foals (n = 93) were divided into two treatment groups; Group A were dewormed at 2 and 5 months of age with a fenbendazole/ ivermectin/praziquantel product, while Group B were dewormed monthly, alternating between the above‐ mentioned product and an oxfendazole/pyrantel embonate product. Mares (n = 99) were divided into three groups; Group A were dewormed twice (early summer and winter) with fenbendazole/ivermectin/praziquantel, Group B were dewormed with the same product only when egg counts exceeded 300 eggs per gram, and Group C were dewormed every 2 months, alternating between the two products. Health data was collected at 2‐monthly intervals for 13 months. Foals in Group A had significantly higher ascarid and strongylid faecal egg counts compared to Group B, but no significant differences were observed between mare groups. There were no differences between groups with regards to body weight and body condition score. One foal in Group B developed diarrhoea during the monitoring period. No colic signs were reported in any group during the study. Reducing anthelmintic treatment intensity can lead to higher ascarid and strongylid egg counts in foals on stud farms; however, no negative health consequences were observed within the timeframe of this study. Longer monitoring periods are needed to assess the effects of increased egg shedding on subsequent foal crops. v Control of endoparasites on stud farms
Made with FlippingBook
RkJQdWJsaXNoZXIy OTc5MDU=